Status | Study |
Completed |
Study Name: A European Post-Authorisation Observational Study Of Patients With Hereditary Angioedema Condition: Hereditary Angioedema (HAE) Date: 2012-02-16 |
Active, not recruiting |
Study Name: A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary Angioedema Condition: Hereditary Angioedema (HAE) Date: 2011-06-28 Interventions: Drug: icatibant Single dose of icatibant 0.4 mg/kg subcutaneous(SC) up to a maximal dose of 30 mg |
Recruiting |
Study Name: Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) Patients Condition: Hereditary Angioedema Date: 2011-05-19 Interventions: Drug: rhC1INH Patients up to 84 kg will receive one i.v. injection of Ruconest at a dose of 50 U/kg. The |
Withdrawn |
Study Name: Study to Evaluate Ecallantide in Paediatric Patients With Acute Attacks of Hereditary Angioedema Condition: Hereditary Angioedema Date: 2010-12-02 Interventions: Biological: ecallantide 10 - 30mg subcutaneous injection. |
Completed |
Study Name: CINRYZE for the Treatment of Hereditary Angioedema Attacks in Children Under the Age of 12 Condition: Hereditary Angioedema Date: 2010-03-24 Interventions: Biological: CINRYZE Other Name: C1 inhibitor [human] |
Completed |
Study Name: A Study of Icatibant in Patients With Acute Attacks of Hereditary Angioedema (FAST-3) Condition: Hereditary Angioedema Date: 2009-06-02 Interventions: Drug: Icatibant Single subcuta |
Completed |
Study Name: Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema (HAE) Condition: Hereditary Angioedema Date: 2007-07-12 Interventions: Drug: Icatibant Icatibant: a s |
Completed |
Study Name: Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks Condition: Hereditary Angioedema Date: 2007-04-17 Interventions: Biological: C1 esterase inhibitor [human] (C1INH-nf) |
Completed |
Study Name: Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE) Condition: Hereditary Angioedema Date: 2007-04-04 Interventions: Drug: ecallantide solution for SC injection, one 30 mg dose per HAE attack |
Completed |
Study Name: Efficacy Study of DX-88 (Ecallantide) to Treat Acute Attacks of Hereditary Angioedema (HAE) Condition: Hereditary Angioedema Date: 2007-04-04 Interventions: Drug: ecallantide dose of 30 m |